mRECIST RESPONSE
ASSESSMENT FOR TACE
After TACE, your tumour may appear larger on imaging because of surrounding necrosis and oedema — but still show a complete response. mRECIST focuses exclusively on the arterially enhancing viable tumour, not total lesion size, giving an accurate picture of how much living cancer tissue remains.
analyticsAt a Glance
- check_circlemRECIST defines response based on change in the arterially enhancing viable tumour diameter — not total lesion size
- check_circleComplete response (CR): no arterial enhancement in any target lesion — all viable tumour is absent on imaging
- check_circleRECIST 1.1 is systematically misleading after TACE — a lesion that grows due to necrosis but shows no enhancement would be called progressive disease by RECIST and complete response by mRECIST
- check_circleFirst post-TACE imaging should be contrast-enhanced MRI or multiphasic CT at 4–6 weeks
Why Standard RECIST Fails After TACE — and What mRECIST Does Instead
RECIST 1.1 — the standard oncology response framework — measures the longest diameter of target lesions. In systemic therapy, tumour shrinkage directly correlates with treatment efficacy. After TACE, this correlation breaks down completely: successful TACE induces central necrosis with surrounding inflammatory oedema, causing the total lesion to increase in size on imaging while the viable tumour component simultaneously disappears. RECIST 1.1 would classify this response as progressive disease — the exact opposite of the true response.
“Measuring a TACE-treated lesion with RECIST is like measuring the weight of a fruit after removing its flesh — the shell gets heavier as the flesh disappears, giving the opposite signal from the truth. mRECIST measures only the flesh.”
The Arterial Enhancement Signal
HCC is hypervascular — its feeding arterial supply produces bright arterial enhancement (the 'arterial blush') on multiphasic contrast imaging that distinguishes viable HCC from necrotic tissue. After TACE, necrotic tumour tissue loses its vascular supply and no longer enhances. mRECIST uses this signal specifically: measuring the diameter of the arterially enhancing viable component in each target lesion, ignoring the surrounding necrosis and oedema that inflates total lesion size.
Which Imaging Modality Is Best for mRECIST Assessment?
Contrast-enhanced MRI with gadolinium is the gold standard — it has higher sensitivity for detecting small residual viable tumour at the periphery of the treated zone compared to CT. Multiphasic contrast-enhanced CT is acceptable, particularly after cTACE where Lipiodol retention provides additional information. For DEB-TACE, where no Lipiodol signal is present, MRI is strongly preferred. Unenhanced CT or ultrasound cannot reliably assess mRECIST response.
mRECIST Response Categories: Definitions and Clinical Implications
mRECIST classifies response into four categories based on change in the sum of the longest diameters of the arterially enhancing viable tumour in all target lesions.
| Response Category | Abbreviation | Definition | Clinical Implication |
|---|---|---|---|
| Complete Response | CR | Disappearance of any intratumoral arterial enhancement in all target lesions — no viable tumour detected | Best possible outcome — may indicate complete pathological necrosis; continue surveillance; bridge to transplant if listed; consider no further TACE if durable CR at 8–12 weeks |
| Partial Response | PR | ≥30% decrease in the sum of diameters of viable (arterially enhancing) target lesions, taking baseline sum as reference | Treatment is working — continue current TACE protocol; re-assess at next imaging interval; residual viable tumour requires retreatment targeting |
| Stable Disease | SD | Neither sufficient shrinkage to qualify as PR (≥30% decrease) nor sufficient increase to qualify as PD (<20% increase); no new lesions | No significant change — consider whether technique modification (superselective vs lobar) would improve response; discuss at MDT; may continue if disease stable and liver function preserved |
| Progressive Disease | PD | ≥20% increase in the sum of diameters of viable (enhancing) target lesions, or appearance of one or more new intrahepatic or extrahepatic lesions | TACE unresponsive — reassess BCLC staging; extrahepatic spread → systemic therapy; new intrahepatic only → reassess candidacy for TACE or switch to Y-90 / ablation / systemic combination |
mRECIST vs RECIST 1.1: Why the Difference Matters Clinically
The following examples illustrate how the same imaging findings lead to opposite response classifications under the two frameworks — and why mRECIST is the correct tool after TACE.
RECIST 1.1 Assessment
- Scenario 1: Lesion grows from 4 cm to 5 cm but shows no arterial enhancementRECIST: Progressive disease (>20% increase in diameter). Action prompted: stop TACE, consider systemic therapy. Incorrect — the lesion grew because of necrosis and oedema, not viable tumour growth.
- Scenario 2: Total lesion unchanged at 4 cm; viable component reduced from 3 cm to 1 cmRECIST: Stable disease (no significant change in total diameter). Correct response not captured — a major partial response to viable tumour reduction is invisible to RECIST.
- Scenario 3: Lesion contracts from 5 cm to 3 cm (all necrotic, no enhancement)RECIST: Partial response (≥30% decrease). Correct category by chance — but the correct reason (complete viable tumour ablation) is not reflected.
mRECIST Assessment (Correct)
- Scenario 1: Lesion 5 cm total, 0 cm enhancing — all necroticmRECIST: Complete response (no arterial enhancement). Correct — tumour is dead. Continue on current protocol; TACE has achieved its goal.
- Scenario 2: Total lesion 4 cm; viable enhancing component 1 cmmRECIST: Partial response (viable component reduced from 3 cm to 1 cm = 67% decrease). Correctly reflects major treatment response; plan targeted retreatment of 1 cm viable rim.
- Scenario 3: Lesion 3 cm total, 0 cm enhancingmRECIST: Complete response. Correctly identifies complete viable tumour ablation regardless of residual necrotic tissue size.
Post-TACE Imaging Protocol: What Should Happen and When
The timing, modality, and interpretation of post-TACE imaging are as important as the TACE procedure itself — incorrect imaging protocol leads to incorrect response classification.
- 1
Timing: 4–6 Weeks Post-TACE
The first post-TACE response assessment should occur 4–6 weeks after the procedure — allowing post-embolisation oedema to partially resolve while viable residual tumour remains detectable. Earlier imaging (<4 weeks) overestimates response due to persisting inflammatory change; later imaging (>8 weeks) risks missing residual viable tumour that could be treated promptly.
- 2
Modality: Contrast MRI Preferred
Request a multiphasic liver MRI with IV gadolinium contrast (including arterial, portal venous, delayed, and hepatobiliary phases if gadoxetate is used). For cTACE follow-up, CT is acceptable and allows Lipiodol retention assessment. For DEB-TACE, MRI is preferred — no Lipiodol signal is present.
- 3
Request mRECIST Reporting Explicitly
Most radiologists default to RECIST 1.1 unless specifically asked for mRECIST. When scheduling your follow-up imaging, ensure the radiology request states: 'Post-TACE mRECIST response assessment — please measure the arterially enhancing viable component of each target lesion and compare to baseline.' Providing the pre-TACE imaging for comparison is essential.
- 4
Identify All Four Lesion Categories
The mRECIST assessment covers target lesions (measurable enhancing HCC ≥1 cm treated with TACE), non-target lesions (other HCC not selected as targets), new lesions (any new HCC appearing since the last assessment), and non-hepatic disease (extrahepatic lymph nodes, lung, bone). Response requires assessment of all four categories.
- 5
Correlation with AFP
AFP trajectory should be assessed alongside imaging at every response evaluation. A falling AFP that reaches the normal range is a strong corroboration of complete or major partial response. AFP rising despite radiological CR raises concern for non-target lesion growth or early extrahepatic disease not visible on current imaging.
mRECIST: Key Reference Numbers
The thresholds and response rates relevant to mRECIST assessment in clinical practice.
- ≥30%Decrease in viable tumour diameter required for Partial Response (mRECIST PR)Same threshold as RECIST 1.1 — but applied to the arterially enhancing diameter rather than total lesion diameter.
- ≥20%Increase in viable tumour diameter that defines Progressive Disease (mRECIST PD)Any new lesion, regardless of size, also qualifies as PD — the appearance of new HCC elsewhere in the liver is a critical progression event.
- 25–35%Complete response (mRECIST CR) rate after first TACE in Child-Pugh A HCCRates vary by lesion size, vascularity, and technique — superselective DEB-TACE achieves higher CR rates than non-selective cTACE for the same lesion size.
- 4–6 wkRecommended first post-TACE imaging interval for mRECIST assessmentThe evidence-based timing window that balances resolution of acute inflammatory change and capture of residual viable tumour before it progresses.
More from the TACE Resource Library
Continue exploring TACE response assessment and management decisions.
- Repeat TACE: When to Retreat and When to Stop
- TACE Complications: Liver Failure, Biliary Injury, and Management
- cTACE vs DEB-TACE: Which Technique Is Right for Your HCC?
- TACE Patient Selection: BCLC Staging and Child-Pugh Score
- TACE Survival Data: Evidence from Pivotal Clinical Trials
- TACE Therapy — Complete Treatment Guide
Frequently Asked Questions
Common questions from patients reviewing post-TACE imaging results.
Understanding Your Post-TACE Imaging
My post-TACE CT report says the lesion is 'larger than before' — does this mean the TACE didn't work?
Not necessarily — and this is exactly the scenario where understanding mRECIST vs RECIST matters most. After TACE, the total lesion size commonly increases due to necrosis, oedema, and the inflammatory margin — while the viable tumour component simultaneously shrinks or disappears. The critical question is not whether the total lesion is larger or smaller, but whether arterial enhancement is present within the lesion on the post-contrast arterial phase images. If the radiologist has reported 'no arterial enhancement' or 'no viable HCC' within the treated lesion, the treatment has worked — this is a mRECIST complete response regardless of total lesion size. Ask your radiologist or oncologist to specifically report on the presence or absence of arterial enhancement within the treated zone rather than just the total lesion dimensions.
My AFP has fallen to normal but my imaging shows some residual enhancement — which is correct?
Both pieces of information are important and potentially informative. A normalised AFP alongside residual imaging enhancement raises two possibilities: (1) the residual enhancement is viable HCC that is not yet AFP-producing at a detectable level — in which case retreatment is appropriate; (2) the enhancement represents post-treatment inflammatory or vascular change rather than viable tumour — which can appear similar to viable HCC enhancement on CT but can usually be distinguished on MRI with hepatobiliary phase contrast (gadoxetate). An MRI with hepatobiliary phase imaging after a CT showing equivocal residual enhancement — and a normal AFP — is the correct next investigation before committing to retreatment. Discuss specifically with your hepatobiliary radiologist whether the enhancement pattern is consistent with viable HCC vs benign post-treatment change.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Confused by Your Post-TACE Imaging Report?
CancerFax can arrange a specialist hepatobiliary radiologist review of your post-TACE MRI or CT — interpreting mRECIST response and advising on whether retreatment, surveillance, or transplant pathway continuation is appropriate.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.